Ketamine and Magnesium for Refractory Neuropathic Pain A Randomized, Double-blind, Crossover Trial

被引:0
|
作者
Pickering, Gisele [1 ,2 ]
Pereira, Bruno [3 ]
Morel, Veronique [1 ]
Corriger, Alexandrine [1 ]
Giron, Fatiha [1 ]
Marcaillou, Fabienne [4 ]
Bidar-Beauvallot, Assiya [4 ]
Chandeze, Evelyne [4 ]
Lambert, Celine [3 ]
Bernard, Lise [5 ]
Delage, Noemie [4 ]
机构
[1] Univ Hosp Clermont Ferrand, Clin Pharmacol Dept, Inserm, CIC 1405, F-63000 Clermont Ferrand, France
[2] Clermont Auvergne Univ, Inserm 1107, F-63000 Clermont Ferrand, France
[3] Univ Hosp Clermont Ferrand, Clin Res & Innovat Dept, F-63000 Clermont Ferrand, France
[4] Univ Hosp Clermont Ferrand, Assessment & Treatment Pain Ctr, F-63000 Clermont Ferrand, France
[5] Univ Hosp Clermont Ferrand, Clin Res Temporary Authorizat Dept, F-63000 Clermont Ferrand, France
关键词
SF-36 HEALTH SURVEY; INTRAVENOUS KETAMINE; MORPHINE; SULFATE; QUESTIONNAIRE; METAANALYSIS; VALIDATION; MANAGEMENT; THERAPY;
D O I
10.1097/ALN.0000000000003327
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Ketamine is often used for the management of refractory chronic pain. There is, however, a paucity of trials exploring its analgesic effect several weeks after intravenous administration or in association with magnesium. The authors hypothesized that ketamine in neuropathic pain may provide pain relief and cognitive-emotional benefitversusplacebo and that a combination with magnesium may have an additive effect for 5 weeks. Methods: A randomized, double-blind, crossover, placebo-controlled study (NCT02467517) included 20 patients with neuropathic pain. Each ketamine-naive patient received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulfate (3g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion. Secondary endpoints included pain (at 7, 15, 21 and 28 days) and health-related, emotional, sleep, and quality of life questionnaires. Results: Daily pain intensity was not significantly different between the three groups (n = 20) over 35 days (mean area under the curve = 185 +/- 100, 196 +/- 92, and 187 +/- 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively,P= 0.296). The effect size of the main endpoint was -0.2 (95% CI [-0.6 to 0.3];P= 0.425) for ketamineversusplacebo, 0.2 (95% CI [-0.3 to 0.6];P= 0.445) for placeboversusketamine/magnesium and -0.4 (95% CI [-0.8 to 0.1];P= 0.119) for ketamineversusketamine/magnesium. There were no significant differences in emotional, sleep, and quality of life measures. During placebo, ketamine, and ketamine/magnesium infusions, 10%, 20%, and 35% of patients respectively reported at least one adverse event. Conclusions: The results of this trial in neuropathic pain refuted the hypothesis that ketamine provided pain relief at 5 weeks and cognitive-emotional benefitversusplacebo and that a combination with magnesium had any additional analgesic effect.
引用
收藏
页码:154 / 164
页数:11
相关论文
共 50 条
  • [21] THE USE OF KETAMINE FOR ACUTE TREATMENT OF PAIN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Sin, Billy
    Tatunchak, Tamara
    Paryavi, Mohammad
    Olivo, Maria
    Mian, Usman
    Ruiz, Josel
    Shah, Bupendra
    de Souza, Sylvie
    JOURNAL OF EMERGENCY MEDICINE, 2017, 52 (05): : 601 - 608
  • [22] Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial
    van Seventer, R.
    Bach, F. W.
    Toth, C. C.
    Serpell, M.
    Temple, J.
    Murphy, T. K.
    Nimour, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (08) : 1082 - 1089
  • [23] THERAPY WITH NIFEDIPINE IN ASTHMA - A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL
    LIDJI, M
    MOLHO, M
    CHAGNAC, A
    KATZ, I
    BENZARAY, S
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1988, 24 (01): : 1 - 4
  • [24] Effect of modafinil on acute pain: A randomized double-blind crossover study
    Taneja, I
    Bruehl, S
    Robertson, D
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (12): : 1425 - 1427
  • [25] SALBUTAMOL - A DOUBLE-BLIND CROSSOVER TRIAL
    STREETON, JA
    MEDICAL JOURNAL OF AUSTRALIA, 1970, 2 (25) : 1184 - &
  • [26] DOUBLE-BLIND CROSSOVER TRIAL WITH FENFLURAMINE
    NEY, P
    NEAL, T
    MANKU, MS
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1988, 33 (06): : 574 - 574
  • [27] Transcranial direct current stimulation for upper limb neuropathic pain: A double-blind randomized controlled trial
    Lewis, G. N.
    Rice, D. A.
    Kluger, M.
    McNair, P. J.
    EUROPEAN JOURNAL OF PAIN, 2018, 22 (07) : 1312 - 1320
  • [28] A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain
    Raskin, J
    Pritchett, YL
    Wang, FJ
    D'Souza, DN
    Waninger, AL
    Iyengar, S
    Wernicke, JF
    PAIN MEDICINE, 2005, 6 (05) : 346 - 356
  • [29] A DOUBLE-BLIND, CROSSOVER TRIAL OF INTRAVENOUS CLODRONATE IN METASTATIC BONE PAIN
    ERNST, DS
    MACDONALD, RN
    PATERSON, AHG
    JENSEN, J
    BRASHER, P
    BRUERA, E
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1992, 7 (01) : 4 - 11
  • [30] Prospective double-blind crossover trial of ibuprofen in reducing EMG pain
    El-Salem, Khalid
    Shakhatreh, Mohammad
    MUSCLE & NERVE, 2008, 38 (02) : 1016 - 1020